Myriad Genetics Inc. Common Stock (MYGN)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Myriad Genetics as a Graham-style bargain hunter, but the numbers offer little comfort. The company sells molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $190.7 million, down from $213.1 million in fiscal Q2 2025, the quarter ended 2025-06-30. Net loss was $43.2 million, or $0.46 per diluted share; that compares with a $330.5 million net loss, or $3.57 per diluted share, in fiscal Q2 2025. The loss narrowed, but the company still lost money. For fiscal FY2025, the year ended 2025-12-31, revenue was $824.5 million and net loss was $365.9 million, or $3.95 per diluted share. In fiscal FY2024, the year ended 2024-12-31, revenue was $837.6 million and net loss was $127.3 million, or $1.41 per diluted share. Revenue is not growing, and profits are absent. At the 2026-10-13 close of $4.08, FairStock’s P/B is 1.28 and market cap is $390.3 million. Negative ROE of -32.54% and ROCE of -8.60% mean book value is not earning a return. Free cash flow is -$14.2 million, with an FCF yield of -3.6%. The Piotroski F-Score is 2/9 and Altman Z-Score is -1.54, both signs of weak financial health. Debt/equity of 0.69 is manageable, but cash burn matters. There is no Peter Lynch category because the company lost money in each of the last four years. FairStock Score is 51/100. I see no durable moat in these figures. A low price relative to book can be a starting point, but Graham’s margin of safety needs earning power and asset protection. Until revenue stabilizes, net income turns positive, and free cash flow improves, this remains a speculative turnaround, not a proven value compounder.

In plain English: Myriad Genetics sells molecular tests used in cancer and women's health. The business is losing money, sales have been slipping, and it is not generating positive cash flow. At $4.08, the price looks low compared with the value of its assets, but the losses make it hard to call a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer